

TARGETED DRUG DELIVERY USING SULFONAMIDE DERIVATIVES

Patent number:	WO9800173	Also published as:
Publication date:	1998-01-08	 WO9800173 (A)  EP0909184 (A3)  EP0909184 (A2)  EP0909184 (B1)
Inventor:	ZHAO ZHIYANG (US); TOMASSELLI ALFREDO G (US); KOEPLINGER KENNETH A (US); PETERSON TILLIE (US); SUARATO ANTONINO (IT)	
Applicant:	UPJOHN CO (US); ZHAO ZHIYANG (US); TOMASSELLI ALFREDO G (US); KOEPLINGER KENNETH A (US); PETERSON TILLIE (US); SUARATO ANTONINO (IT)	Cited documents:
Classification:		 EP0391799  US5294720  WO9530670  WO9411361  WO8807378 more >>
- International:	A61K47/48; A61K47/48; (IPC1-7): A61K47/48	
- european:	A61K47/48H4	
Application number:	WO1997US10817 19970701	
Priority number(s):	US19960022489P 19960703	

[Report a data error](#)

Abstract of WO9800173

The present invention relates to Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the in-vivo release of a drug that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The drug may be an anticancer agent (or one with other therapeutic properties) carrying a free -NH- which has been derivatized by the attachment of an electrophile containing a moiety such as p-CN- or p-NO₂-pyridinylsulfonyl groups, or p-NO₂- or 2,4 dinitrophenylsulfonyl groups, or suitable derivatives thereof, to make a prodrug. Optionally, the sulfonamide moiety may have attached to it a targeting molecule. The present invention also provides Glutathione S-transferase (GST)/Reduced Glutathione (GSH) as a means for the release of a protected amino derivative that has been conjugated to specific electrophilic moieties via a sulfonamide bond. The precursor is a synthetic intermediate carrying a free -NH- which has been derivatized by the attachment of an electrophile via a sulfonamide bond.

Data supplied from the **esp@cenet** database - Worldwide